Search
Fosamprenavir
go.drugbank.com/drugs/DB01319ApprovedInvestigationalFosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Dichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269Approved[L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
Ezetimibe
go.drugbank.com/drugs/DB00973ApprovedInvestigationalintestinal villi - this prompted studies investigating the effect of ezetimibe on intestinal cholesterol absorption. … [A33313] In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings
Mixtures: EXOTIB-DUOCategories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaOmacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnused to treat accelerated or chronic phase CML. … Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML.
Categories: Heterocyclic Compounds with 4 or More RingsSynonyms: mepesuccinato de omacetaxinaPhosphatidyl serine
go.drugbank.com/drugs/DB00144ApprovedNutraceuticalIn apoptosis, phosphatidyl serine is transferred to the outer leaflet of the plasma membrane. This is part of the process by which the cell is targeted for phagocytosis. … Because of the potentail cognitive benefits of phosphatidylserine, the substance is sold as a dietary supplement to people who believe they can benefit from an increased intake.
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnIts market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide
Lixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 33 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEMCategories: Drugs Used in DiabetesPhenylethanolamine N-methyltransferase
go.drugbank.com/bio_entities/BE0000865TargetEnzymeHumansCatalyzes the transmethylation of nonepinephrine (noradrenaline) to form epinephrine (adrenaline), using S-adenosyl-L-methionine as the methyl donor (PubMed:20496117). Other substrates include phenylethanolamine and octopamine (PubMed:16...
Synonyms: PENTEtidronic acid
go.drugbank.com/drugs/DB01077ApprovedInvestigational[A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901] … [A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.
Categories: Drugs for Treatment of Bone Diseases